Posted by Michael Wonder on 03 Jul 2023
Amneal receives US FDA complete response letter for IPX203
3 July 2023 - Letter requests additional pharmacokinetic data.
Amneal Pharmaceuticals today announced it has received a complete response letter from the US FDA regarding the Company’s new drug application for IPX203 for the treatment of Parkinson’s disease.
